Cerebrovascular Accident Clinical Trial
Official title:
Cognitively-based Treatments of Acquired Dyslexias
Adults who sustain brain damage due to stroke, head injury, or traumatic surgery may develop difficulty reading. This study examines the effectiveness of behavior-based programs to improve reading ability in these individuals.
Acquired disorders of reading (acquired dyslexia) are common in patients with aphasia
subsequent to left hemisphere stroke. Even when language functions recover sufficiently to
enable the patient to return to work, continuing dyslexia often interferes significantly
with job performance. This study will evaluate cognitive therapies for the treatment of
acquired dyslexia.
Each therapy is based upon a cognitive neuropsychological model of reading; the therapies
target specific types of reading deficit and stem from the question of re-learning versus
re-organization of function. The therapies focus on dyslexic disorders stemming from the
following underlying deficits: 1) impaired access to the orthographic word form from the
visual modality (pure alexia); 2) impaired orthographic/phonologic connections
(phonologic/deep dyslexia); and 3) decreased ability to hold phonologic codes in memory
(phonologic text alexia).
Participants in this study will undergo a comprehensive and detailed battery of reading and
reading-related tests to determine the underlying impairment causing the reading deficit.
Based upon the results of these tests, the patient's dyslexic disorder will be characterized
and, if appropriate, the patient will be assigned to one of the treatment programs devised
specifically for that type of deficit. Treatment programs are evaluated for efficacy by
comparing the accuracy and speed of reading pre- and post-treatment.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05477238 -
Oxygen Consumption in Post-stroke Patients During Various Walking Activities Compared to Healthy Controls
|
N/A | |
Completed |
NCT00046293 -
ReoPro and Retavase to Treat Acute Stroke
|
Phase 2 | |
Completed |
NCT04584645 -
A Digital Flu Intervention for People With Cardiovascular Conditions
|
N/A | |
Completed |
NCT01116544 -
Treatment of Chronic Stroke With AMES + EMG Biofeedback
|
N/A | |
Withdrawn |
NCT04991038 -
Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients
|
N/A | |
Active, not recruiting |
NCT02563886 -
Electrically Assisted Movement Therapy
|
N/A | |
Recruiting |
NCT02446730 -
Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome
|
Phase 4 | |
Completed |
NCT02141932 -
Pocket-size Cardiovascular Ultrasound in Stroke
|
N/A | |
Completed |
NCT01915368 -
Determining Optimal Post-Stroke Exercise (DOSE)
|
N/A | |
Recruiting |
NCT01769326 -
Influence of Timing on Motor Learning
|
N/A | |
Recruiting |
NCT02557737 -
Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Upper Extremities
|
Phase 3 | |
Terminated |
NCT01705353 -
The Role of HMGB-1 in Chronic Stroke
|
N/A | |
Completed |
NCT01423201 -
Transient Ischemic Attack (TIA) Triage and Evaluation of Stroke Risk
|
||
Completed |
NCT01656876 -
The Effects of Mirror Therapy on Upper Extremity in Stroke Patients
|
N/A | |
Completed |
NCT01182818 -
Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry Disease
|
N/A | |
Withdrawn |
NCT00573092 -
Analyzing Gene Regions That May Interact With the Effectiveness of High Blood Pressure Drugs
|
N/A | |
Completed |
NCT00542256 -
tDCS and Physical Therapy in Stroke
|
N/A | |
Completed |
NCT00377689 -
Evaluation of an Intervention Program Targeted at Improving Balance and Functional Skills After Stroke
|
Phase 2 | |
Recruiting |
NCT00166751 -
Sonographic Assessment of Laryngeal Elevation
|
N/A | |
Terminated |
NCT00120289 -
Niacin Plus Statin to Prevent Vascular Events
|
Phase 3 |